Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis

Molecular Nutrition and Food Research

Volumn 60, Issue 4, 2016, Pages 922-934

  Johnson, Rabia ^a   Dludla, Phiwayinkosi ^a,b   Joubert, Elizabeth ^c,d   February, Faghri ^e   Mazibuko, Sithandiwe ^a   Ghoor, Samira ^a   Muller, Christo ^a   Louw, Johan ^a  

^a Biomedical Research and Innovation Platform   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c ARC INFRUITEC NIETVOORBIJ   (South Africa)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

Apoptosis; Aspalathin; Cardiomyopathy; Diabetes; Fatty acid oxidation

Indexed keywords

ASPALATHIN; BAX PROTEIN, RAT; CHALCONE DERIVATIVE; GLUCOSE; GLUTATHIONE; METFORMIN; PROTECTIVE AGENT; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ANIMAL; APOPTOSIS; CARDIAC MUSCLE CELL; CELL CULTURE; COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PATHOLOGY; RAT;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; CHALCONES; DRUG THERAPY, COMBINATION; GLUCOSE; GLUTATHIONE; MEMBRANE POTENTIAL, MITOCHONDRIAL; METFORMIN; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 84962693099     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500656     Document Type: Article

References (42)

1. Alexander, C. M., Landsman, P. B., Teutsch, S. M., Haffner, S. M., NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52, 1210-1214.
2. Lee, T. I., Kao, Y. H., Chen, Y. C., Huang, J. H. et al., Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Diabetes Res. Clin. Pract. 2013, 100, 330-339.
3. Mahgoub, M. A., Abd-Elfattah, A. S., Diabetes mellitus and cardiac function. Mol. Cell. Biochem. 1998, 180, 59-64.
4. Ansley, D. M., Wang, B., Oxidative stress and myocardial injury in the diabetic heart. J. Pathol. 2013, 229, 232-241.
5. Flores-Mateo, G., Carrillo-Santisteve, P., Elosua, R., Guallar, E. et al., Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies. Am. J. Epidemiol. 2009, 170, 135-147.
6. Khullar, M., Al-Shudiefat, A. A., Ludke, A., Binepal, G. et al., Oxidative stress: a key contributor to diabetic cardiomyopathy. Can. J. Physiol. Pharmacol. 2010, 88, 233-240.
7. Flores-Mateo, G., Elosua, R., Rodriguez-Blanco, T., Basora-Gallisa, J. et al., Oxidative stress is associated with an increased antioxidant defense in elderly subjects: a multilevel approach. PloS One 2014, 9, e105881.
8. Mukherjee, S., Banerjee, S. K., Maulik, M., Dinda, A. K. et al., Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. BMC Pharmacol. 2003, 3, 16-25.
9. Abou-El-Hassan, M. A., Rabelink, M. J., van der Vijgh, W. J., Bast, A. et al., A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro. Br. J. Cancer 2003, 89, 2140-2146.
10. Bayeva, M., Sawicki, K. T., Ardehali, H., Taking diabetes to heart-deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J. Am. Heart Assoc. 2013, 2, e000433.
11. Lopaschuk, G. D., Ussher, J. R., Folmes, C. D., Jaswal, J. S. et al., Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010, 90, 207-258.
12. Stanley, W. C., Lopaschuk, G. D., McCormack, J. G., Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 1997, 34, 25-33.
13. Fillmore, N., Mori, J., Lopaschuk, G. D., Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br. J. Pharmacol. 2014, 171, 2080-2090.
14. Inzucchi, S. E., Metformin and heart failure: innocent until proven guilty. Diabetes Care 2005, 28, 2585-2587.
15. Erejuwa, O. O., Sulaiman, S. A., Wahab, M. S., Salam, S. K. et al., Antioxidant protective effect of glibenclamide and metformin in combination with honey in pancreas of streptozotocin-induced diabetic rats. Int. J. Mol. Sci. 2010, 11, 2056-2066.
16. Pandey, K. B., Rizvi, S. I., Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev. 2009, 2, 270-278.
17. Wang, S., Zhang, J., Chen, M., Wang, Y., Delivering flavonoids into solid tumors using nanotechnologies. Expert Opin. Drug Deliv. 2013, 10, 1411-1428.
18. Bahadoran, Z., Mirmiran, P., Azizi, F., Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J. Diabetes Metab. Disord. 2013, 12, 43-52.
19. Esmaeili, M. A., Sonboli, A., Antioxidant, free radical scavenging activities of Salvia brachyantha and its protective effect against oxidative cardiac cell injury. Food Chem. Toxicol. 2010, 48, 846-853.
20. Jiang, F., Chang, C. W., Dusting, G. J., Cytoprotection by natural and synthetic polyphenols in the heart: novel mechanisms and perspectives. Curr. Pharm. Des. 2010, 16, 4103-4112.
21. Zhang, P. Y., Xu, X., Li, X. C., Cardiovascular diseases: oxidative damage and antioxidant protection. Eur. Rev. Med. Pharm. Sci. 2014, 18, 3091-3096.
22. Muller, C. J., Joubert, E., de Beer, D., Sanderson, M. et al., Acute assessment of an aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential. Phytomedicine 2012, 20, 32-39.
23. Son, M. J., Minakawa, M., Miura, Y., Yagasaki, K., Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur. J. Nutr. 2013, 52, 1607-1619.
24. Chen, W., Sudji, I. R., Wang, E., Joubert, E. et al., Ameliorative effect of aspalathin from rooibos (Aspalathus linearis) on acute oxidative stress in Caenorhabditis elegans. Phytomedicine 2013, 20, 380-386.
25. Darvesh, A. S., Carroll, R. T., Bishayee, A., Geldenhuys, W. J. et al., Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents. Expert Rev. Neurother. 2010, 10, 729-745.
26. Baba, H., Ohtsuka, Y., Haruna, H., Lee, T. et al., Studies of anti-inflammatory effects of Rooibos tea in rats. Pediatr. Int. 2009, 51, 700-704.
27. Dludla, P. V., Muller, C. J., Louw, J., Joubert, E. et al., The cardioprotective effect of an aqueous extract of fermented rooibos (Aspalathus linearis) on cultured cardiomyocytes derived from diabetic rats. Phytomedicine 2014, 21, 595-601.
28. Singh, B. K., Singh, A., Kumar, V., Ameliorative effect of adjunct therapy of metformin with atorvastatin on streptozotocin-induced diabetes mellitus in rats. Drug Res. 2015, 66, 28-32.
29. Han, Z., Achilonu, M. C., Kendrekar, P. S., Joubert, E. et al., Concise and scalable synthesis of aspalathin, a powerful plasma sugar-lowering natural product. J. Nat. Prod. 2014, 77, 583-588.
30. Nugent, C., Prins, J. B., Whitehead, J. P., Wentworth, J. M. et al., Arachidonic acid stimulates glucose uptake in 3T3-L1 adipocytes by increasing GLUT1 and GLUT4 levels at the plasma membrane. Evidence for involvement of lipoxygenase metabolites and peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2001, 276, 9149-9157.
31. Mazibuko, S. E., Muller, C. J., Joubert, E., de Beer, D. et al., Amelioration of palmitate-induced insulin resistance in C(2)C(1)(2) muscle cells by rooibos (Aspalathus linearis). Phytomedicine 2013, 20, 813-819.
32. Fillmore, N., Lopaschuk, G. D., Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. Biochim. Biophys. Acta 2013, 1833, 857-865.
33. Belke, D. D., Larsen, T. S., Gibbs, E. M., Severson, D. L., Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am. J. Physiol. Endocrinol. Metab. 2000, 279, E1104-E1113.
34. Kenno, K. A., Severson, D. L., Lipolysis in isolated myocardial cells from diabetic rat hearts. Am. J. Physiol. 1985, 249, H1024-H1030.
35. Herrero, P., Peterson, L. R., McGill, J. B., Matthew, S. et al., Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J. Am. Coll. Cardiol. 2006, 47, 598-604.
36. Kantor, P. F., Lucien, A., Kozak, R., Lopaschuk, G. D., The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Cir. Res. 2000, 86, 580-588.
37. Nagendran, J., Waller, T. J., Dyck, J. R., AMPK signalling and the control of substrate use in the heart. Mol. Cell. Endocrinol. 2013, 366, 180-193.
38. Coort, S. L., Bonen, A., van der Vusse, G. J., Glatz, J. F. et al., Cardiac substrate uptake and metabolism in obesity and type-2 diabetes: role of sarcolemmal substrate transporters. Mol. Cell. Biochem. 2007, 299, 5-18.
39. Sun, X., Chen, R. C., Yang, Z. H., Sun, G. B. et al., Taxifolin prevents diabetic cardiomyopathy in vivo and in vitro by inhibition of oxidative stress and cell apoptosis. Food. Chem. Toxicol. 2014, 63, 221-232.
40. Mattiasson, G., Shamloo, M., Gido, G., Mathi, K. et al., Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat. Med. 2003, 9, 1062-1068.
41. Brand, M. D., Esteves, T. C., Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell. Metab. 2005, 2, 85-93.
42. Niture, S. K., Jaiswal, A. K., Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 2012, 287, 9873-9886.